Arrowhead Pharmaceuticals, Inc. (ARWR) financial statements (2022 and earlier)
Company profile
| Business Address |
177 E COLORADO BLVD PASADENA, CA 91105 |
| State of Incorp. | DE |
| Fiscal Year End | September 30 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2021 TTM | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 330 | 368 | 315 | 259 | 77 | 66 | 85 | ||
| Cash and cash equivalents | 92 | 184 | 144 | 222 | 30 | 25 | 85 | ||
| Short-term investments | 239 | 183 | 172 | 37 | 46 | 41 | |||
| Receivables | 0 | 10 | 1 | 1 | 0 | 0 | 0 | ||
| Prepaid expense | 5 | 4 | 4 | 3 | 1 | 1 | 1 | ||
| Other current assets | 3 | 2 | 2 | 3 | 1 | 1 | 4 | ||
| Total current assets: | 338 | 385 | 322 | 265 | 79 | 68 | 91 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 17 | 17 | 16 | ✕ | ✕ | ✕ | |||
| Property, plant and equipment | 52 | 49 | 31 | 23 | 14 | 16 | 15 | ||
| Long-term investments and receivables | 218 | 246 | 137 | 44 | |||||
| Long-term investments | 218 | 246 | 137 | 44 | |||||
| Intangible assets, net (including goodwill) | 13 | 14 | 15 | 17 | 19 | 20 | 22 | ||
| Intangible assets, net (excluding goodwill) | 13 | 14 | 15 | 17 | 19 | 20 | 22 | ||
| Other noncurrent assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Total noncurrent assets: | 300 | 326 | 200 | 85 | 33 | 36 | 38 | ||
| TOTAL ASSETS: | 639 | 710 | 523 | 350 | 112 | 104 | 128 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 26 | 33 | 20 | 19 | 12 | 12 | 21 | ||
| Accounts payable | 4 | 9 | 7 | 8 | 3 | 4 | 12 | ||
| Accrued liabilities | 19 | 14 | 5 | 7 | 5 | 5 | 5 | ||
| Employee-related liabilities | 3 | 10 | 8 | 5 | 4 | 3 | 4 | ||
| Deferred revenue | 109 | 111 | 19 | 78 | ✕ | ✕ | ✕ | ||
| Debt | 0 | 0 | 0 | ||||||
| Deferred rent credit | 0 | 0 | ✕ | ✕ | |||||
| Derivative instruments and hedges, liabilities | 1 | 2 | |||||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | 6 | 3 | ||
| Other liabilities | 0 | 0 | 0 | 0 | 0 | ||||
| Other undisclosed current liabilities | 3 | 2 | 1 | 0 | |||||
| Total current liabilities: | 137 | 147 | 41 | 97 | 12 | 19 | 26 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 22 | 23 | 20 | 2 | 2 | 3 | |||
| Long-term debt, excluding current maturities | 2 | 2 | 3 | ||||||
| Operating lease, liability | 22 | 23 | 20 | ✕ | ✕ | ✕ | |||
| Liabilities, other than long-term debt | 106 | 131 | 9 | 2 | 2 | 5 | |||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | 2 | 5 | ||
| Deferred revenue | 106 | 131 | 5 | ✕ | ✕ | ✕ | |||
| Deferred rent credit | 4 | 2 | ✕ | ✕ | |||||
| Other liabilities | 0 | 0 | 0 | ||||||
| Other undisclosed noncurrent liabilities | (20) | ||||||||
| Total noncurrent liabilities: | 129 | 155 | 20 | 9 | 4 | 4 | 8 | ||
| Total liabilities: | 266 | 301 | 61 | 106 | 16 | 23 | 33 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 373 | 409 | 462 | 245 | 96 | 81 | 96 | ||
| Preferred stock | 0 | ||||||||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 1,080 | 1,053 | 965 | 664 | 583 | 514 | 494 | ||
| Accumulated other comprehensive income (loss) | (0) | (0) | 0 | (0) | (0) | 0 | 0 | ||
| Accumulated deficit | (708) | (645) | (504) | (419) | (487) | (433) | (398) | ||
| Stockholders' equity attributable to noncontrolling interest | (1) | (1) | (1) | (1) | |||||
| Total stockholders' equity: | 373 | 409 | 462 | 244 | 95 | 81 | 95 | ||
| TOTAL LIABILITIES AND EQUITY: | 639 | 710 | 523 | 350 | 112 | 104 | 128 | ||
Income statement (P&L) ($ in millions)
| 12/31/2021 TTM | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 144 | 138 | 88 | 169 | 16 | 31 | 0 | |
| Gross profit: | 144 | 138 | 88 | 169 | 16 | 31 | 0 | |
| Operating expenses | (333) | (287) | (181) | (108) | (72) | (68) | (82) | |
| Operating income (loss): | (188) | (149) | (93) | 61 | (56) | (37) | (82) | |
| Nonoperating income | 5 | 8 | 9 | 7 | 1 | 3 | 0 | |
| Investment income, nonoperating | (1) | |||||||
| Other nonoperating income (expense) | 0 | 2 | (1) | 0 | 1 | 0 | ||
| Income (loss) from continuing operations before income taxes: | (183) | (141) | (85) | 68 | (54) | (34) | (82) | |
| Income tax expense | (0) | (0) | (0) | (0) | (0) | (0) | ||
| Other undisclosed loss from continuing operations | (0) | |||||||
| Net income (loss) available to common stockholders, diluted: | (183) | (141) | (85) | 68 | (54) | (34) | (82) | |
Comprehensive Income ($ in millions)
| 12/31/2021 TTM | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (183) | (141) | (85) | 68 | (54) | (34) | (82) | |
| Comprehensive income (loss): | (183) | (141) | (85) | 68 | (54) | (34) | (82) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (0) | (0) | 0 | (0) | (0) | 0 | 0 | |
| Comprehensive income (loss), net of tax, attributable to parent: | (183) | (141) | (84) | 68 | (55) | (34) | (82) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.